EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structural basis for varying drug resistance of SARS-CoV-2 M pro E166 variants

Morgan A Esler, Ke Shi, Joseph A Rollie, Renee Delgado, Jyoti Vishwakarma, Agnieszka Dabrowska, Janani Prahlad, Seyed Arad Moghadasi, Reuben S Harris iD, Hideki Aihara iD

mBio · 2025

DOI: 10.1128/mbio.02624-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Morgan A Esler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Resistance, Viral, Coronavirus 3C Proteases, Antiviral Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) has an essential role in the virus lifecycle and, accordingly, it is a target for antiviral drugs. Multiple studies have identified an M pro mutation (E166V) that confers strong resistance to clinically relevant inhibitors, including nirmatrelvir, but the underlying mechanism is not fully understood. Here, we report on crystal structures of SARS-CoV-2 M pro E166V in complex with nirmatrelvir, ensitrelvir, and bofutrelvir. The structures suggest that resistance is caused in part by the loss of a direct hydrogen bond and also, especially for nirmatrelvir, by a steric clash with the substituted valine residue. In comparison, the binding of bofutrelvir shows greater flexibility, which may help alleviate this steric effect and allow bofutrelvir to fit the mutant active site despite the loss of a direct polar contact. Thermal stability analyses also corroborate E166V most severely affecting the binding of nirmatrelvir and, to lesser and different extents, ensitrelvir and bofutrelvir. We further show that E166I causes even more severe nirmatrelvir resistance, whereas E166A and E166L have much milder effects. These studies shed light on the molecular mechanisms of a key M pro drug resistance mutation and may help inform the design of next-generation inhibitors. IMPORTANCE Using a combination of high-resolution X-ray crystallographic and biochemical analyses, we reveal the molecular mechanisms by which a mutation in the severe acute respiratory syndrome coronavirus 2 main protease (M pro ) confers strong resistance against clinically relevant antiviral drugs that inhibit M pro activity. The results presented here may help inform the design of next-generation inhibitors to combat the problem of therapy resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Drug Resistance, ViralCoronavirus 3C ProteasesAntiviral AgentsHumansCrystallography, X-RayMutationModels, MolecularCOVID-19 Drug TreatmentCOVID-19Protein ConformationLactamsLeucineNitrilesProline

Stichwörter der Autor:innen

BofutrelvirEnsitrelvirNirmatrelvirSARS-CoV-2antiviral drugcrystal structuredrug resistance mechanismsviral protease

Substanzen

Coronavirus 3C ProteasesAntiviral Agentsnirmatrelvir3C-like proteinase, SARS-CoV-2LactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
  • Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA.
  • Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, Texas, USA.

ORCID-Profile: Reuben S Harris, Hideki Aihara

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • HHS | NIH | National Institute of General Medical Sciences (NIGMS)
  • NCRR NIH HHS

Zitieren

APA

Esler, M. A., Shi, K., Rollie, J. A., Delgado, R., Vishwakarma, J., Dabrowska, A., Prahlad, J., Moghadasi, S. A., Harris, R. S., & Aihara, H. (2025). Structural basis for varying drug resistance of SARS-CoV-2 M pro E166 variants. mBio. https://doi.org/10.1128/mbio.02624-24

Vancouver

Esler MA, Shi K, Rollie JA, Delgado R, Vishwakarma J, Dabrowska A, et al. Structural basis for varying drug resistance of SARS-CoV-2 M pro E166 variants. mBio. 2025. doi:10.1128/mbio.02624-24

BibTeX
@article{Esler2025,
  author = {Esler, Morgan A and Shi, Ke and Rollie, Joseph A and Delgado, Renee and Vishwakarma, Jyoti and Dabrowska, Agnieszka and Prahlad, Janani and Moghadasi, Seyed Arad and Harris, Reuben S and Aihara, Hideki},
  title = {Structural basis for varying drug resistance of SARS-CoV-2 M pro E166 variants},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.02624-24}
}
Kostenlos starten →